<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> in skeletal muscle is a major risk factor for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in women with <z:hpo ids='HP_0000147'>polycystic ovary</z:hpo> syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>However, the molecular mechanisms underlying skeletal muscle <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and the insulin-sensitizing effect of <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> in vivo are less well characterized </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: We determined molecular mediators of insulin signaling to <z:chebi fb="105" ids="17234">glucose</z:chebi> transport in skeletal muscle biopsies of 24 PCOS patients and 14 matched control subjects metabolically characterized by euglycemic-hyperinsulinemic clamps and indirect calorimetry, and we examined the effect of 16 weeks of treatment with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Impaired insulin-mediated total (R(d)) oxidative and nonoxidative <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal (NOGD) was paralleled by reduced insulin-stimulated Akt phosphorylation at Ser473 and Thr308 and AS160 phosphorylation in muscle of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Akt phosphorylation at Ser473 and Thr308 correlated positively with R(d) and NOGD in the insulin-stimulated state </plain></SENT>
<SENT sid="5" pm="."><plain>Serum free <z:chebi fb="51" ids="17347">testosterone</z:chebi> was inversely related to insulin-stimulated R(d) and NOGD in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Importantly, the <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>-mediated improvement in insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, which did not fully reach <z:mpath ids='MPATH_458'>normal</z:mpath> levels, was accompanied by normalization of insulin-mediated Akt phosphorylation at Ser473 and Thr308 and AS160 phosphorylation </plain></SENT>
<SENT sid="7" pm="."><plain>AMPK activity and phosphorylation were similar in the two groups and did not respond to <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Impaired insulin signaling through Akt and AS160 in part explains <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> at the molecular level in skeletal muscle in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e>, and the ability of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> to enhance insulin sensitivity involves improved signaling through Akt and AS160 </plain></SENT>
<SENT sid="9" pm="."><plain>Moreover, our data provide correlative evidence that <z:e sem="disease" ids="C0206081" disease_type="Disease or Syndrome" abbrv="">hyperandrogenism</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCOS</z:e> may contribute to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
</text></document>